Trillium Asset Management LLC Sells 220 Shares of Becton, Dickinson and Company (NYSE:BDX)

Trillium Asset Management LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.9% in the first quarter, according to its most recent filing with the SEC. The fund owned 24,866 shares of the medical instruments supplier’s stock after selling 220 shares during the quarter. Trillium Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $6,152,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. ProVise Management Group LLC boosted its position in shares of Becton, Dickinson and Company by 4.8% during the 1st quarter. ProVise Management Group LLC now owns 37,061 shares of the medical instruments supplier’s stock valued at $9,171,000 after acquiring an additional 1,696 shares during the last quarter. Orion Portfolio Solutions LLC lifted its position in Becton, Dickinson and Company by 17.8% in the first quarter. Orion Portfolio Solutions LLC now owns 19,233 shares of the medical instruments supplier’s stock worth $4,759,000 after buying an additional 2,902 shares during the last quarter. Wilkins Investment Counsel Inc. bought a new stake in Becton, Dickinson and Company in the first quarter worth $565,000. Lord Abbett & CO. LLC lifted its position in Becton, Dickinson and Company by 51.2% in the first quarter. Lord Abbett & CO. LLC now owns 185,865 shares of the medical instruments supplier’s stock worth $45,992,000 after buying an additional 62,963 shares during the last quarter. Finally, HBK Sorce Advisory LLC lifted its position in Becton, Dickinson and Company by 5.7% in the first quarter. HBK Sorce Advisory LLC now owns 3,167 shares of the medical instruments supplier’s stock worth $784,000 after buying an additional 172 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roland Goette sold 3,300 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total value of $781,209.00. Following the completion of the sale, the executive vice president now owns 11,308 shares of the company’s stock, valued at $2,676,942.84. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,615 shares of company stock worth $2,033,381. 0.31% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BDX shares. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Monday. Barclays increased their target price on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. Evercore ISI reduced their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price on the stock. Finally, Citigroup reduced their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus price target of $280.14.

Becton, Dickinson and Company Stock Down 0.4 %

NYSE BDX traded down $1.00 during trading on Friday, hitting $230.74. The company’s stock had a trading volume of 1,068,283 shares, compared to its average volume of 1,431,097. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The company has a market cap of $66.69 billion, a PE ratio of 50.82, a P/E/G ratio of 2.05 and a beta of 0.42. The business’s 50 day simple moving average is $232.52 and its 200-day simple moving average is $236.58. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The firm had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter in the previous year, the company posted $2.86 earnings per share. The company’s revenue was up 4.6% compared to the same quarter last year. On average, equities analysts anticipate that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Monday, June 10th were given a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 1.65%. The ex-dividend date of this dividend was Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.